Daiichi Sankyo Company, Limited (DSKYF) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - General secteur d'activité. Le siège social de l'entreprise est situé à Tokyo, Japan. Le PDG actuel est Hiroyuki Okuzawa.
DSKYF a date d'introduction en bourse 2008-06-24, 18,726 employés à temps plein, cotée sur le Other OTC, une capitalisation boursière de $32.23B.
Daiichi Sankyo Company, Limited is a Tokyo-based pharmaceutical company founded in 1899 that researches, develops, manufactures, and markets a diverse portfolio of prescription and over-the-counter medicines globally. The company's core therapeutic areas include oncology, cardiovascular disease, diabetes, pain management, and infectious disease, with key products such as Enhertu (trastuzumab deruxtecan) for cancer treatment, edoxaban for anticoagulation, and teneligliptin for diabetes management. Beyond pharmaceuticals, Daiichi Sankyo operates across consumer health, vaccines, animal health, cosmetics, and medical devices. The company has established strategic collaborations, including a partnership with Guardant Health to develop companion diagnostics, and maintains a strong commitment to innovation across multiple healthcare segments.
